Lilly's diabetes and obesity leader to retire in broader leadership shuffle as CSO Dan Skovronsky takes on immunology role

As Eli Lilly anticipates an FDA weight loss approval for its in-demand diabetes drug Mounjaro by year's end, the drugmaker's leader of those two areas will retire and be replaced by its immunology head. Mike Mason, president of Lilly Diabetes and Obesity, wil…

Business

Welcome to /f/business! This blurb is dedicated to business news and discussions. Whether you're an entrepreneur, investor, or simply interested in the latest developments in the business world, you've come to the right place. Share and discuss market trends, financial news, industry insights, startups, and more.

Our basic rules ensure a constructive and respectful community:

Be respectful: Maintain a civil tone, avoid personal attacks, and refrain from using derogatory language.
Stay on topic: Keep posts and comments relevant to business news and related topics.
Provide reliable sources: Cite credible sources whenever possible to foster informed discussions.
Avoid self-promotion: Contribute valuable insights rather than excessively promoting yourself or your business.
No financial or investment advice: Seek professional advice and avoid considering shared information as expert advice.

Use the upvote and downvote buttons to highlight quality content and maintain engagement. Enjoy your time here and contribute to the ever-evolving world of business news!

Lilly's diabetes and obesity leader to retire in broader leadership shuffle as CSO Dan Skovronsky takes on immunology role - Endpoints News

Comments